Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 6/2015

01.05.2015 | Original Article

18F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility

verfasst von: Manuel Gómez-Río, Nathalie Testart Dardel, Alicia Santiago Chinchilla, Antonio Rodríguez-Fernández, Gonzalo Olivares Granados, Raquel Luque Caro, Mercedes Zurita Herrera, Clara E. Chamorro Santos, Pablo Lardelli-Claret, José M. Llamas-Elvira

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The follow-up of treated low-grade glioma (LGG) requires the evaluation of subtle clinical changes and MRI results. When the result is inconclusive, additional procedures are required to assist decision-making, such as the use of advanced MRI (aMRI) sequences and nuclear medicine scans (SPECT and PET). The aim of this study was to determine whether incorporating 18F-fluorocholine PET/CT in the follow-up protocol for treated LGG improves diagnostic accuracy and clinical utility.

Methods

This was a prospective case-series study in patients with treated LGG during standard follow-up with indeterminate clinical and/or radiological findings of tumour activity. All patients underwent clinical evaluation, aMRI, 201Tl-SPECT and 18F-fluorocholine PET/CT. Images were interpreted by visual evaluation complemented with semiquantitative analysis.

Results

Between January 2012 and December 2013, 18 patients were included in this study. The final diagnosis was established by histology (five surgical specimens, one biopsy specimen) or by consensus of the Neuro-Oncology Group (11 patients) after a follow-up of >6 months (mean 14.9 ± 2.72 months). The global diagnostic accuracies were 90.9 % for aMRI (38.8 % inconclusive), 69.2 % for 201Tl-SPECT (11.1 % inconclusive), and 100 % for 18F-fluorocholine PET/CT. 201Tl-SPECT led correctly to a change in the initial approach in 38.9 % of patients but might have led to error in 27.8 %. The use of 18F-fluorocholine PET/CT alone rather than 201Tl-SPECT led correctly to a change in the approach suggested by routine follow-up in 72.2 % of patients and endorsed the approach in the remaining 27.8 %.

Conclusion

Our results support the need to complement structural MRI with aMRI and nuclear medicine procedures in selected patients. 18F-Fluorocholine PET/CT can be useful in the individualized management of patients with treated LGG with uncertain clinical and/or radiological evidence of tumour activity.
Literatur
1.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.CrossRefPubMedCentralPubMed Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.CrossRefPubMedCentralPubMed
2.
Zurück zum Zitat Gómez-Río M, Martínez Del Valle Torres D, Rodríguez-Fernández A, Llamas-Elvira JM, Ortega Lozano S, Ramos Font C, et al. (201)Tl-SPECT in low-grade gliomas: diagnostic accuracy in differential diagnosis between tumour recurrence and radionecrosis. Eur J Nucl Med Mol Imaging. 2004;31:1237–43.CrossRefPubMed Gómez-Río M, Martínez Del Valle Torres D, Rodríguez-Fernández A, Llamas-Elvira JM, Ortega Lozano S, Ramos Font C, et al. (201)Tl-SPECT in low-grade gliomas: diagnostic accuracy in differential diagnosis between tumour recurrence and radionecrosis. Eur J Nucl Med Mol Imaging. 2004;31:1237–43.CrossRefPubMed
3.
Zurück zum Zitat Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, et al. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med. 2013;54:2046–54.CrossRefPubMed Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, et al. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med. 2013;54:2046–54.CrossRefPubMed
4.
Zurück zum Zitat Rahmathulla G, Marko NF, Weil RJ. Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations. J Clin Neurosci. 2013;20:485–502.CrossRefPubMed Rahmathulla G, Marko NF, Weil RJ. Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations. J Clin Neurosci. 2013;20:485–502.CrossRefPubMed
5.
Zurück zum Zitat Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van der Bent M. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906–20.CrossRefPubMed Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van der Bent M. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906–20.CrossRefPubMed
6.
Zurück zum Zitat Arbizu J, Domínguez PD, Diez-Valle R, Vigil C, García-Eulate R, Zubieta JL, et al. Neuroimaging in brain tumors. Rev Esp Med Nucl. 2011;30:47–65.CrossRefPubMed Arbizu J, Domínguez PD, Diez-Valle R, Vigil C, García-Eulate R, Zubieta JL, et al. Neuroimaging in brain tumors. Rev Esp Med Nucl. 2011;30:47–65.CrossRefPubMed
7.
Zurück zum Zitat Herholz K, Coope D, Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol. 2007;6:711–24.CrossRefPubMed Herholz K, Coope D, Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol. 2007;6:711–24.CrossRefPubMed
8.
Zurück zum Zitat DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805–14.PubMed DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805–14.PubMed
9.
Zurück zum Zitat Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Suda Y, Sekine T, et al. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res. 1999;90:419–24.CrossRefPubMed Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Suda Y, Sekine T, et al. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res. 1999;90:419–24.CrossRefPubMed
10.
Zurück zum Zitat Ramírez de Molina A, Rodríguez-González A, Gutiérrez R, Martínez-Piñeiro L, Sánchez J, Bonilla F, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002;296:580–3.CrossRefPubMed Ramírez de Molina A, Rodríguez-González A, Gutiérrez R, Martínez-Piñeiro L, Sánchez J, Bonilla F, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002;296:580–3.CrossRefPubMed
11.
Zurück zum Zitat Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 2006;9:358–65.CrossRefPubMed Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 2006;9:358–65.CrossRefPubMed
12.
Zurück zum Zitat Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med. 2007;37:420–8.CrossRefPubMed Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med. 2007;37:420–8.CrossRefPubMed
13.
Zurück zum Zitat Hara T, Kondo T, Hara T, Kosaka N. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg. 2003;99:474–9.CrossRefPubMed Hara T, Kondo T, Hara T, Kosaka N. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg. 2003;99:474–9.CrossRefPubMed
14.
Zurück zum Zitat Kwee SA, Coel MN, Lim J, Ko JP. Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumor evaluation. J Neuroimaging. 2004;14:285–9.CrossRefPubMed Kwee SA, Coel MN, Lim J, Ko JP. Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumor evaluation. J Neuroimaging. 2004;14:285–9.CrossRefPubMed
15.
Zurück zum Zitat Lam WW, Ng DC-E, Wong WY, Ong SC, Yu SW, See SJ. Promising role of [18F]fluorocholine PET/CT vs [18F]fluorodeoxyglucose PET/CT in primary brain tumors – early experience. Clin Neurol Neurosurg. 2011;113:156–61.CrossRefPubMed Lam WW, Ng DC-E, Wong WY, Ong SC, Yu SW, See SJ. Promising role of [18F]fluorocholine PET/CT vs [18F]fluorodeoxyglucose PET/CT in primary brain tumors – early experience. Clin Neurol Neurosurg. 2011;113:156–61.CrossRefPubMed
16.
Zurück zum Zitat Kwee SA, Ko JP, Jiang CS, Watters MR, Coel MN. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology. 2007;244:557–65.CrossRefPubMed Kwee SA, Ko JP, Jiang CS, Watters MR, Coel MN. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology. 2007;244:557–65.CrossRefPubMed
17.
Zurück zum Zitat Mertens K, Ham H, Deblaere K, Kalala JP, Van den Broecke C, Slaets D, et al. Distribution patterns of 18F-labelled fluoromethylcholine in normal structures and tumors of the head: a PET/MRI evaluation. Clin Nucl Med. 2012;37:e196–203.CrossRefPubMed Mertens K, Ham H, Deblaere K, Kalala JP, Van den Broecke C, Slaets D, et al. Distribution patterns of 18F-labelled fluoromethylcholine in normal structures and tumors of the head: a PET/MRI evaluation. Clin Nucl Med. 2012;37:e196–203.CrossRefPubMed
18.
Zurück zum Zitat Mertens K, Bolcaen J, Ham H, Deblaere K, Van den Broecke C, Boterberg T, et al. The optimal timing for imaging brain tumours and other brain lesions with 18F-labelled fluoromethylcholine: a dynamic positron emission tomography study. Nucl Med Commun. 2012;33:954–9.CrossRefPubMed Mertens K, Bolcaen J, Ham H, Deblaere K, Van den Broecke C, Boterberg T, et al. The optimal timing for imaging brain tumours and other brain lesions with 18F-labelled fluoromethylcholine: a dynamic positron emission tomography study. Nucl Med Commun. 2012;33:954–9.CrossRefPubMed
19.
Zurück zum Zitat Roelcke U, Bruehlmeier M, Hefti M, Hundsberger T, Nitzsche EU. F-18 choline PET does not detect increased metabolism in F-18 fluoroethyltyrosine-negative low-grade gliomas. Clin Nucl Med. 2012;37:e1–3.CrossRefPubMed Roelcke U, Bruehlmeier M, Hefti M, Hundsberger T, Nitzsche EU. F-18 choline PET does not detect increased metabolism in F-18 fluoroethyltyrosine-negative low-grade gliomas. Clin Nucl Med. 2012;37:e1–3.CrossRefPubMed
20.
Zurück zum Zitat Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, et al. Central nervous system cancers. J Natl Compr Cancer Netw. 2013;11:1114–51. Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, et al. Central nervous system cancers. J Natl Compr Cancer Netw. 2013;11:1114–51.
21.
Zurück zum Zitat Essig M, Anzalone N, Combs SE, Dörfler À, Lee SK, Picozzi P, et al. MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. AJNR Am J Neuroradiol. 2012;33:803–17.CrossRefPubMed Essig M, Anzalone N, Combs SE, Dörfler À, Lee SK, Picozzi P, et al. MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. AJNR Am J Neuroradiol. 2012;33:803–17.CrossRefPubMed
22.
Zurück zum Zitat Van den Bent M, Wefel J, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583–93.CrossRefPubMed Van den Bent M, Wefel J, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583–93.CrossRefPubMed
23.
Zurück zum Zitat Gómez-Río M, Rodríguez-Fernández A, Ramos-Font C, López-Ramírez E, Llamas-Elvira JM. Diagnostic accuracy of 201-Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging. 2008;35:966–75.CrossRefPubMed Gómez-Río M, Rodríguez-Fernández A, Ramos-Font C, López-Ramírez E, Llamas-Elvira JM. Diagnostic accuracy of 201-Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging. 2008;35:966–75.CrossRefPubMed
24.
Zurück zum Zitat Ortega-Lozano SJ, Del Valle-Torres DM, Gómez-Río M, Llamas-Elvira JM. Thallium-201 SPECT in brain gliomas: quantitative assessment in differential diagnosis between tumor recurrence and radionecrosis. Clin Nucl Med. 2009;34:503–5.CrossRefPubMed Ortega-Lozano SJ, Del Valle-Torres DM, Gómez-Río M, Llamas-Elvira JM. Thallium-201 SPECT in brain gliomas: quantitative assessment in differential diagnosis between tumor recurrence and radionecrosis. Clin Nucl Med. 2009;34:503–5.CrossRefPubMed
25.
Zurück zum Zitat Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, et al. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician’s perspective. J Nucl Med. 2012;53:393–8.CrossRefPubMed Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, et al. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician’s perspective. J Nucl Med. 2012;53:393–8.CrossRefPubMed
26.
Zurück zum Zitat Spaeth N, Wyss MT, Pahnke J, Biollaz G, Lutz A, Goepfert K, et al. Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L-tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat. Eur J Nucl Med Mol Imaging. 2006;33:673–82.CrossRefPubMed Spaeth N, Wyss MT, Pahnke J, Biollaz G, Lutz A, Goepfert K, et al. Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L-tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat. Eur J Nucl Med Mol Imaging. 2006;33:673–82.CrossRefPubMed
27.
Zurück zum Zitat Wyss MT, Spaeth N, Biollaz G, Pahnke J, Alessi P, Trachsel E, et al. Uptake of 18F-fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP (L19), a marker of angiogenesis. J Nucl Med. 2007;48:608–14.CrossRefPubMed Wyss MT, Spaeth N, Biollaz G, Pahnke J, Alessi P, Trachsel E, et al. Uptake of 18F-fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP (L19), a marker of angiogenesis. J Nucl Med. 2007;48:608–14.CrossRefPubMed
28.
Zurück zum Zitat Bisdas S, Ritz R, Bender B, Braun C, Pfannenberg C, Reimold M, et al. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes. Invest Radiol. 2013;48:295–301.CrossRefPubMed Bisdas S, Ritz R, Bender B, Braun C, Pfannenberg C, Reimold M, et al. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes. Invest Radiol. 2013;48:295–301.CrossRefPubMed
29.
Zurück zum Zitat Rahm V, Boxheimer L, Bruehlmeier M, Berberat J, Nitzsche EU, Remonda L, et al. Focal changes in diffusivity on apparent diffusion coefficient MR imaging and amino acid uptake on PET do not colocalize in nonenhancing low-grade gliomas. J Nucl Med. 2014;55:546–50.CrossRefPubMed Rahm V, Boxheimer L, Bruehlmeier M, Berberat J, Nitzsche EU, Remonda L, et al. Focal changes in diffusivity on apparent diffusion coefficient MR imaging and amino acid uptake on PET do not colocalize in nonenhancing low-grade gliomas. J Nucl Med. 2014;55:546–50.CrossRefPubMed
30.
Zurück zum Zitat Filss CP, Galldiks N, Stoffels G, Sabel M, Wittsack HJ, Turowski B, et al. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med. 2014;55:540–5.CrossRefPubMed Filss CP, Galldiks N, Stoffels G, Sabel M, Wittsack HJ, Turowski B, et al. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med. 2014;55:540–5.CrossRefPubMed
31.
Zurück zum Zitat Vöglein J, Tüttenberg J, Weimer M, Gerigk L, Kauczor HU, Essig M, et al. Treatment monitoring in gliomas: comparison of dynamic susceptibility-weighted contrast-enhanced and spectroscopic MRI techniques for identifying treatment failure. Invest Radiol. 2011;46:390–400.CrossRefPubMed Vöglein J, Tüttenberg J, Weimer M, Gerigk L, Kauczor HU, Essig M, et al. Treatment monitoring in gliomas: comparison of dynamic susceptibility-weighted contrast-enhanced and spectroscopic MRI techniques for identifying treatment failure. Invest Radiol. 2011;46:390–400.CrossRefPubMed
32.
Zurück zum Zitat Hicks RJ, Hofman MS. Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol. 2012;9:712–20.CrossRefPubMed Hicks RJ, Hofman MS. Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol. 2012;9:712–20.CrossRefPubMed
Metadaten
Titel
18F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility
verfasst von
Manuel Gómez-Río
Nathalie Testart Dardel
Alicia Santiago Chinchilla
Antonio Rodríguez-Fernández
Gonzalo Olivares Granados
Raquel Luque Caro
Mercedes Zurita Herrera
Clara E. Chamorro Santos
Pablo Lardelli-Claret
José M. Llamas-Elvira
Publikationsdatum
01.05.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2015
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-2997-6

Weitere Artikel der Ausgabe 6/2015

European Journal of Nuclear Medicine and Molecular Imaging 6/2015 Zur Ausgabe